应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
PCRX Pacira Pharmaceuticals
休市中 06-28 16:00:00 EDT
28.61
+0.70
+2.51%
盘后
28.61
+0.00
0.00%
17:21 EDT
最高
28.95
最低
27.89
成交量
233.40万
今开
28.15
昨收
27.91
日振幅
3.80%
总市值
13.32亿
流通市值
13.18亿
总股本
4,655万
成交额
6,659万
换手率
5.07%
流通股本
4,606万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Needham:维持Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至43.00美元。
智通财经 · 05-08
Needham:维持Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至43.00美元。
Pacira Biosciences, Inc.2023财年实现净利润41.96百万美元,同比增加163.73%
自选股智能写手 · 03-08
Pacira Biosciences, Inc.2023财年实现净利润41.96百万美元,同比增加163.73%
美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co
Reuters · 03-07
美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co
Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻
Reuters · 02-27
Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻
Pacira Biosciences Inc盘中异动 下午盘快速拉升5.18%
自选股智能写手 · 01-06
Pacira Biosciences Inc盘中异动 下午盘快速拉升5.18%
加载更多
公司概况
公司名称:
Pacira Pharmaceuticals
所属市场:
NASDAQ
上市日期:
--
主营业务:
Pacira BioSciences, Inc.是一家专业制药公司,专注于医药产品的开发、商业化和制造,该公司专有的DepoFoam药物传递技术,主要用于医院和门诊手术中心。2011年10月28日,美国食品和药物管理局( FDA)批准该公司的新药申请,即公司的主导产品EXPAREL,这是一种脂质体注射布比卡因,酰胺类局麻药表示为渗透进入手术部位,术后镇痛长达72小时。该公司认为EXPAREL解决了长效非阿片类镇痛手术后,一个显著的医疗需要,从而简化手术后疼痛控制和减少阿片类药物用量,从而提高患者的治疗效果,提高医院经济效益。该公司开发的内部销售团队完全致力于EXPAREL商业化,该公司已于2012年4月把产品推出市场。此外,继2013年10月1日生效的一个实验方案,该公司任命CrossLink BioScience, LLC(CrossLink),为一个为期五年的独家第三方分销商推广和销售EXPAREL在美国骨科和脊柱外科手术成立一个团队,如果某些地区和账户如有变更,需要经过双方同意才能调整。 该公司成立于2006年12月,并自2007年3月已开展关于EXPAREL业务。
发行价格:
--
{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":28.61,"timestamp":1719604800000,"preClose":27.91,"halted":0,"volume":2333989,"hourTrading":{"tag":"盘后","latestPrice":28.61,"preClose":28.61,"latestTime":"17:21 EDT","volume":1095380,"amount":31338766.058238,"timestamp":1719609679106},"delay":0,"floatShares":46057464,"shares":46546148,"eps":1.416418,"marketStatus":"休市中","marketStatusCode":7,"change":0.7,"latestTime":"06-28 16:00:00 EDT","open":28.15,"high":28.95,"low":27.89,"amount":66587466.821840994,"amplitude":0.037979,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.416418,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1719820800000},"adr":0,"listingDate":1296709200000,"adjPreClose":27.91,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":28.61,"preClose":28.61,"latestTime":"17:21 EDT","volume":1095380,"amount":31338766.058238,"timestamp":1719609679106},"volumeRatio":2.3698404195506653,"impliedVol":0.7768,"impliedVolPercentile":0.8611},"requestUrl":"/m/hq/s/PCRX","defaultTab":"news","newsList":[{"id":"2433742702","title":"Needham:维持Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至43.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2433742702","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433742702?lang=zh_cn&edition=full","pubTime":"2024-05-08 18:47","pubTimestamp":1715165273,"startTime":"0","endTime":"0","summary":"Needham:维持Pacira BioSciences(PCRX.US)评级,由买入调整至买入评级, 目标价由45.00美元调整至43.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050818480287e028e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050818480287e028e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2417794322","title":"Pacira Biosciences, Inc.2023财年实现净利润41.96百万美元,同比增加163.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2417794322","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417794322?lang=zh_cn&edition=full","pubTime":"2024-03-08 00:24","pubTimestamp":1709828695,"startTime":"0","endTime":"0","summary":"12月31日,Pacira Biosciences, Inc.公布财报,公告显示公司2023财年净利润为41.96百万美元,同比增加163.73%;其中营业收入为6.75亿美元,同比增加1.20%,每股基本收益为0.91美元。从资产负债表来看,Pacira Biosciences, Inc.总负债7.04亿美元,其中短期债务17.44百万美元,资产负债比为2.24,流动比率为0.06。机构评级:截至2023年12月31日,当前有10家机构对Pacira Biosciences, Inc.目标价做出预测,其中目标均价为45.30美元,其中最低目标价为36.00美元,最高目标价为57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403080025018760fe42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403080025018760fe42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2417781874","title":"美国研究综述-Highpeak Energy、Nordstrom、Victoria'S Secret & Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2417781874","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2417781874?lang=zh_cn&edition=full","pubTime":"2024-03-07 14:49","pubTimestamp":1709794169,"startTime":"0","endTime":"0","summary":" 路透社3月7日 - 华尔街证券分析师周四修改了对几家美国上市公司的评级和目标价,其中包括 Highpeak Energy、Nordstrom 和 Victoria'S Secret & Co。公司要闻 * Highpeak Energy Inc :Gerdes Energy Research将其评级从买入下调至卖出 * Nordstrom Inc :杰富瑞将其评级从买入下调至持有 * 维多利亚的秘密 :摩根大通将其股票评级从 \"中性 \"下调至 \"减持\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4184","BK4539","PCRX","VSCO","BK4095","BK4139","ANF","BK4588","IE00B66KJ199.SGD","BK4505","CPB","BK4212","HPKEW","BK4213","HPK","BK4192","VCCTF","BK4007","JWN","BK4104","EWCZ","IE0031619046.USD","BBIO","CYTK","ZYME","BK4103","VIAV","ELEV","FL","IE00B19Z4B17.USD","WCC","AQST","BK4102","BK4220","DMTK","OSPN","BHVN","ASTH","UNFI","LU1093756325.SGD","IE00B7SZL793.SGD","NEWT","BK4135","BK4020","BK4094","BK4585","LU1093756168.USD","TPVG","BK4196","TARS"],"gpt_icon":0},{"id":"2414877032","title":"Pacira Biosciences Inc 预计每股收益 88 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2414877032","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2414877032?lang=zh_cn&edition=full","pubTime":"2024-02-27 21:59","pubTimestamp":1709042360,"startTime":"0","endTime":"0","summary":" * 帕西拉生物科学公司 将于2月29日公布截至2023年12月31日的财报,预计该公司的季度收入将有所增长。* LSEG 分析师对 Pacira Biosciences Inc 的平均预期为每股收益 88 美分。* 华尔街对 Pacira Biosciences Inc 的 12 个月目标价中位数为 45.00 美元,高于其最新收盘价 29.74 美元。2月27日 - 上一季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX"],"gpt_icon":0},{"id":"2401599595","title":"Pacira Biosciences Inc盘中异动 下午盘快速拉升5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2401599595","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2401599595?lang=zh_cn&edition=full","pubTime":"2024-01-06 02:25","pubTimestamp":1704479117,"startTime":"0","endTime":"0","summary":"北京时间2024年01月06日02时25分,Pacira Biosciences Inc股票出现异动,股价大幅上涨5.18%。Pacira Biosciences Inc股票所在的制药行业中,整体跌幅为0.03%。Pacira Biosciences Inc公司简介:Pacira BioSciences Inc 是一家提供非阿片类药物疼痛管理和再生健康解决方案的供应商,致力于为医疗保健从业者及其患者推进和改善结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024010602251887e63bf9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024010602251887e63bf9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","PCRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.0222},{"period":"3month","weight":-0.0209},{"period":"6month","weight":-0.152},{"period":"1year","weight":-0.2759},{"period":"ytd","weight":-0.152}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0344},{"period":"3month","weight":0.0404},{"period":"6month","weight":0.145},{"period":"1year","weight":0.2422},{"period":"ytd","weight":0.145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pacira BioSciences, Inc.是一家专业制药公司,专注于医药产品的开发、商业化和制造,该公司专有的DepoFoam药物传递技术,主要用于医院和门诊手术中心。2011年10月28日,美国食品和药物管理局( FDA)批准该公司的新药申请,即公司的主导产品EXPAREL,这是一种脂质体注射布比卡因,酰胺类局麻药表示为渗透进入手术部位,术后镇痛长达72小时。该公司认为EXPAREL解决了长效非阿片类镇痛手术后,一个显著的医疗需要,从而简化手术后疼痛控制和减少阿片类药物用量,从而提高患者的治疗效果,提高医院经济效益。该公司开发的内部销售团队完全致力于EXPAREL商业化,该公司已于2012年4月把产品推出市场。此外,继2013年10月1日生效的一个实验方案,该公司任命CrossLink BioScience, LLC(CrossLink),为一个为期五年的独家第三方分销商推广和销售EXPAREL在美国骨科和脊柱外科手术成立一个团队,如果某些地区和账户如有变更,需要经过双方同意才能调整。 该公司成立于2006年12月,并自2007年3月已开展关于EXPAREL业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.042499},{"month":2,"riseRate":0.692308,"avgChangeRate":0.029842},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.007802},{"month":4,"riseRate":0.571429,"avgChangeRate":0.037069},{"month":5,"riseRate":0.571429,"avgChangeRate":0.025955},{"month":6,"riseRate":0.428571,"avgChangeRate":0.019619},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.00631},{"month":8,"riseRate":0.538462,"avgChangeRate":0.017969},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.008174},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.026814},{"month":11,"riseRate":0.692308,"avgChangeRate":0.066842},{"month":12,"riseRate":0.538462,"avgChangeRate":0.032185}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pacira Pharmaceuticals(PCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pacira Pharmaceuticals(PCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}